Imeglimin

Imeglimin is an experimental drug candidate for the treatment of Type 2 diabetes. It is being developed by Poxel and Sumitomo Dainippon Pharma. Imeglimin works by targeting the mitochondria to enhance glucose-stimulated insulin secretion and insulin sensitivity, and to preserve beta cell mass and function.

Mechanism of action

Imeglimin's mechanism of action is unique and it acts on three main target organs involved in glucose regulation: the liver, muscle, and the pancreas. It is the first clinical candidate in a new class of oral anti-diabetic agents, the Glimins. Imeglimin acts on the mitochondria and specifically improves bioenergetics. It enhances glucose-stimulated insulin secretion and insulin sensitivity, and it preserves beta cell mass and function, which allows for sustained glucose lowering effects.

Clinical trials

Imeglimin has completed Phase 1 and Phase 2 development in over 1,200 subjects in the U.S., EU and Japan. In the U.S. and EU, Imeglimin has successfully completed Phase 2 development in over 850 patients. In Japan, Imeglimin has completed a Phase 2b clinical trial in 299 treatment-naïve patients and a Phase 3 program is currently ongoing.

See also

• Type 2 diabetes
• Poxel
• Sumitomo Dainippon Pharma
• Mitochondria
• Glimins

Imeglimin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia